$2.50
arrow_drop_down3.10%Key Stats | |
---|---|
Open | $2.55 |
Prev. Close | $2.58 |
EPS | -1.11 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $155.30M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 2.49 | 2.56 |
52 Week Range | 1.81 | 5.13 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.11 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024